Pharmacologic and genetic inhibition of NF-κB results in decrease invasion, angiogenesis, clonogenicity, tumorigenicity and metastasis in various pre-clinical models of prostate cancer [46–48]. The gene discussed is NFKB1; the disease is prostate cancer.